The Latest
Policymakers Spotlight GLP-1 Counterfeits, Costs
Policymakers Spotlight GLP-1 Counterfeits, Costs-A bipartisan group of House Energy and Commerce Committee members have sent a letter to the Food and Drug Administration (FDA) requesting a briefing from the agency about the presence of counterfeit Ozempic and other similar products in the nation’s medical supply chain. The lawmakers express concerns about potential gaps in …
Continue reading “Policymakers Spotlight GLP-1 Counterfeits, Costs”
VIEW DOWNLOAD
Listen to the
Health on the Hill Podcast
Health on the Hill provides updates on the current happenings in health care within the Federal Government and on Capitol Hill
Capabilities
Capabilities
Our Team
Our Team
The professionals at Hart Health Strategies have bipartisan, bicameral, legislative experience and also have multi-talented backgrounds in health-related fields.